ArticleScientific reports2026
Human umbilical cord mesenchymal stem cells derived exosomes enhance the therapeutic efficacy of anti-miR-10b in glioblastoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma multiforme (GBM) remains a highly aggressive brain tumor with limited therapeutic options. MicroRNA-10b (miR-10b) is consistently overexpressed in GBM and absent in normal astrocytes, making it a potential therapeutic target. In this study, we evaluated the feasibility of using human umbilical cord mesenchymal stem cell (hUC-MSC)-derived exosomes as delivery vehicles for Locked Nucleic Acid anti-miR-10b-5p (LNA-anti-10b) in U87MG glioblastoma cells. Exosomes were isolated by ultracentrifugation and loaded with LNA-anti-10b. Delivery efficiency was compared with lipofectamine-mediated transfection. The functional effects of exosome-loaded anti-10b (E-LNA-anti-10b) were assessed in both 2D and 3D culture systems. Cell viability and apoptosis were evaluated using Annexin V/PI, AO/PI, and MTT assays, while migration assays assessed cellular aggressiveness. The expression of validated miR-10b target genes and epithelial-mesenchymal transition (EMT)-related markers was analyzed by quantitative RT-PCR and Western blotting. hUC-MSC-derived exosomes efficiently delivered LNA-anti-10b to U87MG cells in both 2D and 3D culture models. E-LNA-anti-10b treatment was associated with enhanced reductions in cell viability, proliferation, migration, and expression of EMT-associated markers. Notably, naïve hUC-MSC-derived exosomes also exhibited intrinsic anti-proliferative and anti-migratory effects. Together, these findings indicate that hUC-MSC-derived exosomes possess inherent anti-tumor properties in GBM models and can functionally enhance the effects of LNA-anti-10b delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.